Unknown

Dataset Information

0

Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device.


ABSTRACT: INTRODUCTION:Drug inhalation via a dry-powder inhaler (DPI) is a convenient, time efficient alternative to nebulizers in the treatment of cystic fibrosis (CF). Efficient drug administration via DPIs depends on the device resistance and adequate (? 45L/min) inspiratory flows and volumes generated by individuals. Dry-powder mannitol is delivered using a RS01 breath-actuated device developed by Plastiape, for Pharmaxis. The study aim was to determine in vivo if CF patients' inspiratory flows and volumes are adequate to use the RS01 DPI device. MATERIALS AND METHODOLOGY:An open, non-interventional study; enrolled 25 CF subjects, aged ? 6 years with FEV1 ? 30 to < 90‰ predicted. Inspiratory flows and volumes were measured when subjects inhaled in a controlled manner through the RS01 device in series with a spirometer. RESULTS:The mean inspiratory volume (IV) of CF subjects was 1.83L ± 0.97. Their achieved mean ± SD peak inspiratory flow (PIF) was 75.5 ± 27.2L/min. Twenty-three subjects (92%) achieved PIF of > 45L/min with the inhaler device; eighteen of those subjects (78%) had a baseline FEV1 of > 1L. CONCLUSION:Use of the RS01 DPI device allowed adequate inspiratory flow and volume for dispersion of dry-powder mannitol in CF patients.

SUBMITTER: Elkins MR 

PROVIDER: S-EPMC3933773 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device.

Elkins Mark R MR   Robinson Philip P   Anderson Sandra D SD   Perry Clare P CP   Daviskas Evangelia E   Charlton Brett B  

The open respiratory medicine journal 20140124


<h4>Introduction</h4>Drug inhalation via a dry-powder inhaler (DPI) is a convenient, time efficient alternative to nebulizers in the treatment of cystic fibrosis (CF). Efficient drug administration via DPIs depends on the device resistance and adequate (≥ 45L/min) inspiratory flows and volumes generated by individuals. Dry-powder mannitol is delivered using a RS01 breath-actuated device developed by Plastiape, for Pharmaxis. The study aim was to determine in vivo if CF patients' inspiratory flow  ...[more]

Similar Datasets

| S-EPMC3933772 | biostudies-literature
| S-EPMC5553717 | biostudies-literature
| S-EPMC7829465 | biostudies-literature
| S-EPMC7905605 | biostudies-literature
| S-EPMC9237582 | biostudies-literature
| S-EPMC7947512 | biostudies-literature
| S-EPMC4267517 | biostudies-literature
| S-EPMC9227944 | biostudies-literature
| S-EPMC8060712 | biostudies-literature
| S-EPMC9639188 | biostudies-literature